Compare CRMT & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | LEXX |
|---|---|---|
| Founded | 1981 | 2004 |
| Country | United States | Canada |
| Employees | N/A | 7 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 16.5M |
| IPO Year | 2026 | N/A |
| Metric | CRMT | LEXX |
|---|---|---|
| Price | $2.13 | $0.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $29.50 | $1.50 |
| AVG Volume (30 Days) | ★ 946.4K | 81.9K |
| Earning Date | 06-11-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,390,932,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.92 | $601.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $0.46 |
| 52 Week High | $62.55 | $1.55 |
| Indicator | CRMT | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 21.83 | 45.49 |
| Support Level | $1.38 | $0.57 |
| Resistance Level | $13.68 | $0.70 |
| Average True Range (ATR) | 1.49 | 0.04 |
| MACD | -0.43 | 0.00 |
| Stochastic Oscillator | 6.98 | 33.51 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.